A comparative study of protein expression in primary colorectal cancer and synchronous hepatic metastases: The significance of matrix metalloproteinase-1 expression as a predictor of liver metastasis

Scandinavian Journal of Gastroenterology

Volumn 45, Issue 2, 2010, Pages 217-225

  Kim, Young Wan ^a   Ko, Yong Taek ^a   Kim, Nam Kyu ^a   Chung, Hyun Cheol ^a   Min, Byung Soh ^a   Lee, Kang Young ^a   Park, Jong Pil ^a   Kim, Hoguen ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

Colonic neoplasm; Liver metastasis; Protein expression

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; INTERSTITIAL COLLAGENASE; MATRILYSIN; PROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; VASCULOTROPIN;

ADULT; ARTICLE; CANCER RECURRENCE; COLORECTAL CANCER; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; PREOPERATIVE PERIOD; PRIMARY TUMOR; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; STAINING;

CARCINOEMBRYONIC ANTIGEN; COLORECTAL NEOPLASMS; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MATRIX METALLOPROTEINASE 1; MATRIX METALLOPROTEINASE 7; MIDDLE AGED; TISSUE INHIBITOR OF METALLOPROTEINASES; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 76749161799     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.3109/00365520903453158     Document Type: Article

References (33)

1. Yang Y, Forslund A, Remotti H, Lönnroth C, Andersson M, Brevinge H, et al. p53 mutations in primary tumors and subsequent liver metastases are related to survival in patients with colorectal carcinoma who undergo liver resection. Cancer 2001;91:727-736
2. De Jong KP, Stellema R, Karrenbeld A, Koudstaal J, Gouw AS, Sluiter WJ, et al. Clinical relevance of transforming growth factor alpha, epidermal growth factor receptor, p53 and Ki67 in colorectal liver metastases and corresponding primary tumor. Hepatology 1998;28:971-979
3. Nitti D, Belluco C, Montesco MC, Bertorelle R, Da Pian PP, Fassina A, et al. Nuclear p53 protein expression in resected hepatic metastases from colorectal cancer: an independent prognostic factor of survival. Eur J Cancer 1998;34:851-855
4. Bird NC, Mangnall D, Majeed AW. Biology of colorectal liver metastases: A review. J Surg Oncol 2006;94:68-80.
5. Rudmik LR, Magliocco AM. Molecular mechanisms of hepatic metastasis in colorectal cancer. J Surg Oncol 2005;92:347-359
6. Neal CP, Garcea G, Doucas H, Manson MM, Sutton CD, Dennison AR, et al. Molecular prognostic markers in resectable colorectal liver metastases: a systematic review. Eur J Cancer 2006;42:1728-1743
7. Jessup JM, Petrick AT, Toth CA, Ford R, Meterissian S, O'Hara CJ, et al. Carcinoembryonic antigen: Enhancement of liver colonisation through retention of human colorectal carcinoma cells. Br J Cancer 1993;67:464-470 (Pubitemid 23077638)
8. Gangopadhyay A, Lazure DA, Thomas P. Adhesion of colorectal carcinoma cells to the endothelium is mediated by cytokines from CEA stimulated Kupffer cells. Clin Exp Metastasis 1998;16:703-712
9. Folkman J, Watson K, Ingber D, Hanahan D. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 1989;339:58-61.
10. Witton CJ, Hawe SJ, Cooke TG, Bartlett JM. Cyclooxygenase 2 (COX2) expression is associated with poor outcome in ER-negative, but not ER-positive, breast cancer. Histopathology 2004;45:47-54.
11. Carrasco JL, Jover L. Estimating the generalized concordance correlation coefficient through variance components. Biometrics 2003;59:849-858
12. Kirkegaard T, Edwards J, Tovey S, McGlynn LM, Krishna SN, Mukherjee R, et al. Observer variation in immunohistochemical analysis of protein expression, time for a change? Histopathology 2006;48:787-794
13. Adachi Y, Inomata M, Kakisako K, Sato K, Shiraishi N, Kitano S, et al. Histopathologic characteristics of colorectal cancer with liver metastasis. Dis Colon Rectum 1999;42:1053-1056 (Pubitemid 29383836)
14. Duffy MJ, Van Dalen A, Haglund C, Hansson L, Klapdor R, Lamerz R, et al. Clinical utility of biochemical markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines. Eur J Cancer 2003;39:718-727
15. Carriquiry LA, Pineyro A. Should carcinoembryonic antigen be used in the management of patients with colorectal cancer? Dis Colon Rectum 1999;42:921-929
16. Shiozawa J, Ito M, Nakayama T, Nakashima M, Kohno S, Sekine I, et al. Expression of matrix metalloproteinase-1 in human colorectal carcinoma. Mod Pathol 2000;13:925-933
17. Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 1999;230:309-318
18. Park JK, Kim NK, Lee KY, Lee WJ, Kim BR, Sohn SK, et al. Prognostic factors affecting survival rate following hepatic resection for metastatic colorectal cancer. J Korean Surg Soc 2001;61:583-587
19. Jenkins LT, Milikan KW, Bines SD, Staren ED, Doolas A. Hepatic resection for metastatic colorectal cancer. Am Surg 1997;63:605-610 (Pubitemid 27268583)
20. Jessup JM, Ishii S, Mitzoi T, Edmiston KH, Shoji Y. Carcinoembryonic antigen facilitates experimental metastasis through a mechanism that does not involve adhesion to liver cells. Clin Exp Metastasis 1999;17:481-488
21. Thomas P, Toth Ca, Saini KS, Jessup JM, Steele G. The structure metabolism and function of the carcinoembryonic antigen gene family. Biochim Biophys Acta 1990;1032:177-189
22. Noe V, Fingleton B, Jacobs K, Crawford HC, Vermeulen S, Steelant W, et al. Release of an invasion promoter E-cadherin fragment by matrilysin and stromelysin 1. J Cell Sci 2000;114:111-118
23. Murray GI, Duncan ME, O'Neil P, Melvint WT, Fothergill JE, et al. Matrix metalloproteinase-1 is associated with poor prognosis in colorectal cancer. Nat Med 1996;2:461-462
24. Sunami E, Tsuno N, Osada T, Saito S, Kitayama J, Tomozawa S, et al. MMP-1 is a prognostic marker for hematogenous metastasis of colorectal cancer. Oncologist 2000;5:108-114
25. Oberg A, Hoyhtya M, Tavelin B, Stenling R, Lindmark G. Limited value of preoperative serum analyses of matrix metalloproteinases (MMP-2, MMP-9) and tissue inhibitors of matrix metalloproteinases (TIMP-1, TIMP-2) in colorectal cancer. Anticancer Res 2000;20: 1085-1091
26. Waas ET, Wobbes T, Ruers T, Lomme RM, Hendriks T. Circulating gelatinases and tissue inhibitor of metalloproteinase- 1 in colorectal cancer metastatic liver disease. Eur J Surg Oncol 2006;32:756-763
27. Ballantyne GH, Quin J. Surgical treatment of liver metastases in patients with colorectal cancer. Cancer 1993;71:4252-4266
28. Folkman J. Tumor angiogenesis: Therapeutic implications. N Engl Med 1971;285:1182-1186
29. Dvorak HF. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis, and a potential target for diagnosis and therapy. J Clin Oncol 2002;20:4368-4380
30. Nigel CB, David M, Ali WM. Biology of colorectal liver metastases: A Review. J Surg Oncol 2006;94:68-80.
31. Murphy AN, Unsworth EJ, Stetler-Stevenson WG. Tissue inhibitor of metalloproteinases-2 inhibits bFGF-induced human microvascular endothelial cell proliferation. J Cell Physiol 1993;157:351-358
32. Schnaper HW, Grant DS, Stetler-Stevenson WG, Fridman R, D'Orazi G, Murphy AN, et al. Type IV collagenase(s) and TIMPs modulate endothelial cell morphogenesis in vitro. J Cell Physiol 1993;156:235-246
33. Pozzi A, LeVine WF, Gardner HA. Low plasma levels of matrix metalloproteinase 9 permit increased tumor angiogenesis. Oncogene 2002;21:272-281